About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Products containing omega-3 fatty acids, such as krill oil and fish oils, have been effective in lowering triglyceride levels. Although no data have suggested that the low-density lipoprotein-cholesterol (LDL-C) increases associated with some omega-3 fatty acid formulations lead to adverse outcomes, these elevations in LDL-C levels may compromise the achievement of lipid targets. Thus, there is a need for agents that can lower triglyceride levels without increasing LDL-C levels.
J. Chris Bradberry, PharmD; and Daniel E. Hilleman, PharmD
Activated Prothrombin Complex Concentrates for the Reversal of Anticoagulant-Associated Coagulopathy
Managing hemorrhaging after the use of warfarin and other anticoagulants is challenging. Although an FDA-approved product, FEIBA, has been used as an offlabel anticoagulant-reversal agent, the potential risks of thrombosis associated with activated prothrombin complex concentrates must be carefully weighed.
Nadia I. Awad, PharmD; and Craig Cocchio, PharmD, BCPS
Hospital Pharmacies Could Face New Pressures
With the Patient Protection and Affordable Care Act going into effect in 2014, hospitals are scrambling to ensure that their formularies meet federal standards.
Therapies for breast cancer, melanoma, lung cancer, and neuroendocrine tumors
Modest Changes Walk Narrow Political Line
Stricter labeling requirements for ER and LA opioids might not be enough.
Vigorous Monitoring Is Crucial
Avoiding dangerous lapses in infection-control practices
Matthew Grissinger, RPh, FASCP
Sheila Sarnoski-Brocavich, BS, MS, PharmD, BCACP, CGP; and Olga Hilas, PharmD, MPH, BCPS, CGP
FDA approvals, drug indications, and updates
Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (Stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma
Marvin M. Goldenberg, PhD, RPh, MS